U.S. Cervical Cancer Screening Market by Test Type (PAP, HPV), Kit Type (PAP, HPV), End User (Hospitals, Laboratories, Physicians’ Offices & Clinics) - Global Forecast to 2020
The global cervical cancer screening market was approximately $15 billion in 2014 and is estimated to grow at a CAGR of 7.0% to reach nearly $22 billion by 2020. PAP test is the largest segment of the global market. However, HPV/co-test will be the fastest-growing product segment during the forecast period.
This report segments the global cervical cancer screening market by test, and end user. Based on type of test, the global market is segmented into PAP test, and HPV test/co-testing.
On the basis of end users, the global cervical cancer diagnosis market is categorized into hospitals, laboratories, and physician’s offices and clinics. Laboratories segment is the major end users of the global market in 2014. Based on geography, the global market is broadly divided into North America, Europe, Asia-Pacific, and RoW.
Growth of this market is driven by growth in aging female population and rising prevalence rate of cervical cancer, high incidence rate of HPV infections, increasing number of awareness programs for cervical cancer diagnostic, and government initiatives and funding. Breakthrough products and technologies, and significant growth in the HPV test market provide new growth opportunities to players in the global market. However, Changes in regulatory guidelines for cervical cancer screening, and use of HPV vaccines are the key factors that are limiting growth of this market. In addition, uncertain reimbursement scenario is the key market challenges.
Some of the major players operating in the global cervical cancer screening market are Hologic Corporation, Becton, Dickinson and Company, Qiagen N.V., and Hoffmann-La Roche.
Want to explore hidden markets that can drive new revenue in U.S. Cervical Cancer Screening Market?
The volume market is not covered in this market report.
Particular |
Scope |
|
Geography |
|
|
Historical Years |
2012-2013 |
|
Base Year |
2014 |
|
Projected Year |
2015-2020 |
|
Revenue Currency |
USD ($) |
Market Segmentation
This research report categorizes the global cervical cancer screening market on the basis of type of test, and end users.
Cervical Cancer Screening Market, by Test
- Pap tests
- HPV test/ Co-testing
Cervical Cancer Screening Market, y End User
- Hospitals
- Laboratories
- Physician’s offices and clinics
Cervical Cancer Screening Market, by Geography
- North America
- Europe
- Asia-Pacific
- RoW (Rest of the World)
The global cervical cancer screening market is expected to grow at a single–digit CAGR of 7.0% to reach $22 billion by 2020 from ~$15 million in 2014. Major factors fueling growth of this market are, growth in aging female population and rising prevalence rate of cervical cancer, high incidence rate of HPV infection, increasing number of awareness programs for cervical cancer screening, and government initiatives and funding. However Changes in regulatory guidelines for cervical cancer diagnostic, and use of HPV vaccines are restricting the growth of this market.
The global cervical cancer screening market is broadly segmented into major two segments on basis of type of test, namely, Pap test, and HPV test/ Co-testing. On the basis of end users, the global market is categorized into hospitals, laboratories, and physician’s offices and clinics. Laboratories segment was the major end users of the global market in 2014.
Geographically, the global market is broadly divided into North America, Europe, Asia-Pacific, and RoW. Some of the major players operating in the global market are Hologic Corporation, Becton, Dickinson and Company, Qiagen N.V., and Hoffmann-La Roche.
Global Cervical Cancer Screening Market Scenario, by Test Type, 2014
Global Cervical Cancer Screening Market Scenario, by End User, 2014
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Table of Contents
1 Introduction
1.1 Objectives of the Study
1.2 Markets Covered
1.3 Stakeholders
1.4 Market Scope
2 Research Methodology
2.1 Market Size Estimation
2.2 Market Crackdown & Data Triangulation
2.3 Market Share Estimation
2.3.1 Key Data Points From Secondary Sources
2.3.2 Key Data Points From Primary Sources
2.3.2.1 Key Industry Insights
2.3.3 Assumptions
3 Executive Summary
4 Premium Insights
5 Market Overview
5.1 Introduction
5.2 Market Segmentation
5.3 Market Dynamics
5.4 Winning Imperatives
5.5 Burning Issues
6 Industry Insights
6.1 Introduction
6.2 Supply Chain Analysis
6.2.1 Key Influencers
6.3 Industry Insights
6.4 Strategic Benchmarking
6.5 Cervical Cancer Incidence Rates
6.6 Regulatory Guidelines and Reimbursement Scenario
6.7 Pricing Analysis
7 Cervical Cancer Screening Market, by Test Type
7.1 Introduction
7.2 PAP Tests
7.3 HPV Tests
8 Cervical Cancer Screening Market, by End Users
8.1 Introduction
8.2 Hospitals
8.3 Laboratories
8.4 Physicians’ Offices & Clinics
9 Geographic Analysis
9.1 North America
9.1.1 U.S.
9.1.1 Canada
9.2 Europe
9.2.1 Germany
9.2.2 U.K.
9.2.3 Rest of Europe (ROE)
9.3 Asia-Pacific
9.3.1 India
9.3.2 China
9.3.3 Japan
9.3.4 Rest of Asia Pacific (ROAPAC)
10.4 Rest of the World (ROW)
10 Competitive Landscape
10.1 Introduction
10.2 Mergers & Acquisitions
10.3 Agreements, Partnerships, Collaborations, Joint Ventures
10.4 New Product Launch
10.5 Approvals
10.6 Expansion
10.7 Others
11 Company Profiles*
*(Overview, Financials, Products & Services, Strategy, & Developments)*
11.1 Introduction
11.2 Hologic, Inc.
11.3 Qiagen N.V.
11.4 Roche Diagnostics
11.5 Quest Diagnostics
11.6 Oncohealth Corporation
11.7 Femasys, Inc.
*Details on Financials, Product & Services, Strategy, & Developments Might Not Be Captured in Case of Unlisted Companies.
12 Appendix
12.1 Insights of Industry Experts
12.2 Discussion Guide
12.3 Introducing Rt: Real-Time Market Intelligence
12.4 Available Customizations
12.5 Related Reports
List of Tables (61 Tables)
Table 1 Cervical Cancer Screening Market Size, By Test Type, 2014 ($Million)
Table 2 Tests Market Size, By Test Type, 2020 ($Million)
Table 3 List of FDA-Approved Products for PAP Tests
Table 4 List of FDA-Approved Products for HPV Tests
Table 5 No. of New Cancer Cases, By Type, 2014
Table 6 Regulatory Landscape Analysis, By Country
Table 7 Percentage Share of Cervical Cancer Cases, By Age Group, 2014
Table 8 Percentage of PAP Test Screening, By Age Group
Table 9 Penetration Rate of Tests, By Type, 2014 Vs. 2020 (%)
Table 10 No. of Cervical Cancer Diagnosis Market, By Test Type, 2012–2020 (Million)
Table 11 No. of PAP Smear Tests, 2012–2020 (Million)
Table 12 No. of HPV Tests, 2012–2020 (Million)
Table 13 North America: Market Size, By Test Type, 2012–2020 ($Million))
Table 14 North America: Cervical Cancer Tests Market Share, By Test Type, 2012-2020 ($Million)
Table 15 North America: Pricing Trend Analysis, PAP and HPV Tests, 2012–2020
Table 16 North America: Cervical Cancer Diagnosis Kits Market Size, By Test Type, 2012–2020 ($Million)
Table 17 North America: Cervical Cancer Kits Market Share, By Test Type, 2012–2020 ($Million)
Table 18 North America: Cervical Cancer Kits Market Size, By End User, 2012–2020 ($Million)
Table 19 North America: Cervical Cancer Screening Market Size, By End User, 2012–2019 ($Million)
Table 20 U.S. : Market Size, By Test Type, 2012–2020 ($Million))
Table 21 U.S. : Cervical Cancer Tests Market Share, By Test Type, 2012-2020 ($Million)
Table 22 U.S. : Pricing Trend Analysis, PAP and HPV Tests, 2012–2020
Table 23 U.S. : Cervical Cancer Diagnosis Kits Market Size, By Test Type, 2012–2020 ($Million)
Table 24 U.S. : Cervical Cancer Kits Market Share, By Test Type, 2012–2020 ($Million)
Table 25 U.S. : Cervical Cancer Kits Market Size, By End User, 2012–2020 ($Million)
Table 26 U.S. : Cervical Cancer Tests Market Size, By End User, 2012–2019 ($Million)
Table 27 Canada : Cervical Cancer Screening Market Size, By Test Type, 2012–2020 ($Million))
Table 28 Canada : Cervical Cancer Tests Market Share, By Test Type, 2012-2020 ($Million)
Table 29 Canada : Pricing Trend Analysis, PAP and HPV Tests, 2012–2020
Table 30 Canada : Cervical Cancer Diagnosis Kits Market Size, By Test Type, 2012–2020 ($Million)
Table 31 Canada : Cervical Cancer Kits Market Share, By Test Type, 2012–2020 ($Million)
Table 32 Canada : Cervical Cancer Kits Market Size, By End User, 2012–2020 ($Million)
Table 33 Canada : Cervical Cancer Tests Market Size, By End User, 2012–2019 ($Million)
Table 34 Europe : Cervical Cancer Screening Market Size, By Test Type, 2012–2020 ($Million))
Table 35 Europe : Pricing Trend Analysis, PAP and HPV Tests, 2012–2020
Table 36 Europe : Cervical Cancer Tests Market Size, By End User, 2012–2019 ($Million)
Table 37 Germany : Cervical Cancer Screening Market Size, By Test Type, 2012–2020 ($Million))
Table 38 Germany : Pricing Trend Analysis, PAP and HPV Tests, 2012–2020
Table 39 Germany : Cervical Cancer Tests Market Size, By End User, 2012–2019 ($Million)
Table 40 U.K. : Market Size, By Test Type, 2012–2020 ($Million))
Table 41 U.K. : Pricing Trend Analysis, PAP and HPV Tests, 2012–2020
Table 42 U.K. Cervical Cancer Tests Market Size, By End User, 2012–2019 ($Million)
Table 43 ROE : Market Size, By Test Type, 2012–2020 ($Million))
Table 44 ROE : Pricing Trend Analysis, PAP and HPV Tests, 2012–2020
Table 45 ROE : Cervical Cancer Tests Market Size, By End User, 2012–2019 ($Million)
Table 46 Asia-Pacific : Market Size, By Test Type, 2012–2020 ($Million))
Table 47 Asia-Pacific : Pricing Trend Analysis, PAP and HPV Tests, 2012–2020
Table 48 Asia-Pacific : Cervical Cancer Tests Market Size, By End User, 2012–2019 ($Million)
Table 49 India : Market Size, By Test Type, 2012–2020 ($Million))
Table 50 India : Cervical Cancer Tests Market Size, By End User, 2012–2019 ($Million)
Table 51 China : Market Size, By Test Type, 2012–2020 ($Million))
Table 52 China : Cervical Cancer Tests Market Size, By End User, 2012–2019 ($Million)
Table 53 Japan : Market Size, By Test Type, 2012–2020 ($Million))
Table 54 Japan : Cervical Cancer Tests Market Size, By End User, 2012–2019 ($Million)
Table 55 ROW : Market Size, By Test Type, 2012–2020 ($Million))
Table 56 ROW : Pricing Trend Analysis, PAP and HPV Tests, 2012–2020
Table 57 ROW : Cervical Cancer Tests Market Size, By End User, 2012–2019 ($Million)
Table 58 New Product Launches, 2012–2015
Table 59 Agreements, Partnerships, and Collaborations, 2012–2015
Table 60 Expansions, 2012–2015
Table 61 Other Developments, 2012–2015
List of Figures (24 Figures)
Figure 1 Research Methodology
Figure 2 Market Size Estimation
Figure 3 Break Down of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Market Data Triangulation Methodology
Figure 5 Tests Market Size, 2014 Vs. 2019 ($Million)
Figure 6 No. of Cervical Cancer Tests, 2014 Vs. 2019 (Million)
Figure 7 Geographical Snapshot: North America Dominated the Cervical Cancer Screening Market in 2014
Figure 8 New Product Launch is the Major Growth Strategy Adopted By the Players in this Market
Figure 9 Market Share, By Test Type, 2014 ($Million)
Figure 10 Cervical Cancer Diagnosis Kits Market Share, By Test Type, 2014 ($Million)
Figure 11 Cervical Cancer Kits Market Share, By End User, 2014 Vs. 2019 ($Million)
Figure 12 Cervical Cancer Tests Market Share, By End User, 2014 Vs. 2019 ($Million)
Figure 13 Global Cervical Cancer Diagnosis Kits Market Share Analysis, By Key Player, 2014 Vs. 2019
Figure 14 Companies Adopted New Product Launches as A Key Growth Strategy From 2012 to 2015
Figure 15 Hologic, Inc. : Company Snapshot
Figure 16 Qiagen N.V. : Company Snapshot
Figure 17 Roche Diagnostics : Company Snapshot
Figure 18 Quest Diagnostics : Company Snapshot
Figure 19 Oncohealth Corporation : Company Snapshot
Figure 20 Femasys, Inc. : Company Snapshot
Figure 21 Neusoft Medical Systems Co. Ltd.: Company Snapshot
Figure 22 Philips Healthcare: Company Snapshot
Figure 23 Siemens Healthcare: Company Snapshot
Figure 24 Toshiba Medical Systems Corporation: Company Snapshot
Growth opportunities and latent adjacency in U.S. Cervical Cancer Screening Market